HC Wainwright Has Negative Forecast for RYTM Q3 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright lowered their Q3 2027 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a research report issued on Wednesday, March 18th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.33 for the quarter, down from their prior forecast of $0.42. HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. The firm had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The business’s quarterly revenue was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.72) EPS.

Other analysts have also issued reports about the stock. Stifel Nicolaus set a $131.00 price target on shares of Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Guggenheim lifted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Needham & Company LLC dropped their target price on shares of Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Citigroup cut their target price on shares of Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating for the company in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $131.13.

Rhythm Pharmaceuticals Trading Down 2.1%

NASDAQ:RYTM opened at $85.86 on Thursday. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The firm has a fifty day simple moving average of $99.45 and a 200 day simple moving average of $102.69. The stock has a market capitalization of $5.86 billion, a PE ratio of -27.61 and a beta of 2.06.

Insiders Place Their Bets

In related news, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer owned 160 shares in the company, valued at approximately $14,329.60. This represents a 97.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 27,267 shares of company stock worth $2,719,955. 6.10% of the stock is owned by company insiders.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds have recently modified their holdings of RYTM. Nisa Investment Advisors LLC lifted its position in Rhythm Pharmaceuticals by 956.9% during the third quarter. Nisa Investment Advisors LLC now owns 13,254 shares of the company’s stock worth $1,339,000 after acquiring an additional 12,000 shares during the last quarter. EFG Asset Management North America Corp. bought a new position in Rhythm Pharmaceuticals during the 3rd quarter worth $2,047,000. Penserra Capital Management LLC bought a new position in Rhythm Pharmaceuticals during the 3rd quarter worth $3,073,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Rhythm Pharmaceuticals during the third quarter worth $4,302,000. Finally, Norges Bank acquired a new stake in shares of Rhythm Pharmaceuticals during the second quarter worth $13,105,000.

Trending Headlines about Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.